Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIO-B
BUYBio-Rad Laboratories, Inc. · Healthcare · United States · $8.3B · Avg Vol: $15K/d
72
StockRankGet insider-trade alerts
Q
55
V
43
M
67
P/E (TTM)
51.6x
ROE
2.5%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Bio-Rad Laboratories is a global leader in the development and manufacture of high-quality products for the life science research and clinical diagnostics markets. Its moat is built on decades of deep scientific expertise and high-barrier-to-entry proprietary laboratory testing technologies.
Loading 1Y...
PRICE (1Y)+1.7%
SMA 50SMA 200
Close
$309.37
RSI (14)
83.7
52W High
$321.12
From 52W High
1.0%
SCORE BREAKDOWN
Quality
55
ROIC
2.7%51.4
ROE
2.5%50.6
GP/Assets
12.7%32.3
Op. Margin
5.8%57.9
FCF/Assets
3.4%61.9
Piotroski
497.4
Int. Cover
5.5x52.9
D/E Ratio
0.20x49.9
Current Ratio
3.21x56.6
Value
43
P/E (TTM)
51.6x20.4
EV/EBITDA
18.2x34.5
P/FCF
23.2x53.3
P/B
1.2x78.7
P/S
3.2x54.7
Div Yield
—N/A
Momentum
67
52W High %
96%95.4
RS 6M
-9%62.1
SMA 50/200
1.01x66.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$8.3B
P/E (Forward)
—
Gross Margin
52.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIO-B are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIO-B | Bio-Rad Laboratories, Inc.(you) | $8.3B | 72 | BUY |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
| ITGR | Integer Holdings Corporation | $3.3B | 73 | BUY |
| GMED | Globus Medical, Inc. | $10.4B | 93 | STRONG BUY |
| PEN | Penumbra, Inc. | $12.5B | 53 | HOLD |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 67 | BUY |
| PODD | Insulet Corporation | $11.3B | 47 | HOLD |
| HAE | Haemonetics Corporation | $3.6B | 89 | STRONG BUY |
| ZBH | Zimmer Biomet Holdings, Inc. | $17.7B | 91 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.5x · Gross margin 50.5%